OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
OKYO Pharma Ltd disclosed that investor Jorey Chernett has filed Amendment No. 2 to a Schedule 13G reporting a significant stake in the company’s common shares. Chernett beneficially owns 3,802,194 shares, representing 9.45% of the outstanding common stock as of the event date.
The filing states that Chernett has sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive authority. It also certifies that the securities were not acquired to change or influence control of OKYO Pharma Ltd, but rather as a passive investment.
OKYO Pharma Limited entered an underwriting agreement with Piper Sandler for an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share. The underwriter has a 30-day option to buy up to 1,622,250 additional shares at the same public price, less fees. Gross proceeds are expected to be approximately $20 million before discounts, commissions and expenses, with all shares sold by the company. Closing is expected on February 17, 2026, subject to customary conditions. OKYO plans to use net proceeds for clinical development of its product candidates, general corporate purposes and working capital. The deal is made under an effective Form F-3 registration, and an updated investor presentation is furnished to investors.
OKYO Pharma Limited is raising capital through an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, for expected gross proceeds of about $20 million before expenses and discounts. The underwriter also has a 30-day option to buy up to 1,622,250 additional shares, which would lift gross proceeds to roughly $23 million if fully exercised.
The company plans to use the net proceeds mainly to fund clinical development of its product candidates, along with general corporate purposes and working capital. OKYO, a clinical-stage biopharma focused on neuropathic corneal pain and inflammatory eye diseases, recently completed a successful phase 2 trial of its lead drug urcosimod and is planning a ~150-patient Phase 2b/3 study.
Dauntless Investment Group, LLC filed Amendment No. 3 to a Schedule 13G reporting a passive ownership position in OKYO Pharma Ltd. The firm reports beneficial ownership of 471,523 common shares, representing 1.17% of the class as of December 31, 2025.
Dauntless, a Delaware single family office/passive investor, reports no sole or shared voting power over OKYO shares. It has sole dispositive power over 360,352 shares and shared dispositive power over 111,171 shares, and certifies the holdings are not for changing or influencing control of OKYO Pharma.
OKYO Pharma Limited intends to offer and sell its ordinary shares in an underwritten public offering, with all shares to be issued by the company. The company expects to grant the underwriter a 30-day option to buy up to an additional 15% of the shares sold.
The deal will be made under an effective Form F-3 shelf registration, with Piper Sandler & Co. as sole book-running manager, and is subject to market conditions. OKYO plans to use net proceeds mainly to fund clinical development of its product candidates, as well as for general corporate purposes and working capital.
OKYO Pharma Limited is conducting a primary offering of ordinary shares on The Nasdaq Capital Market under its F-3 shelf registration. The shares will be sold through an underwritten public offering led by Piper Sandler, with an additional 30-day option for underwriters to buy more shares.
OKYO expects to use the net proceeds for clinical development of its product candidates, general corporate purposes and working capital. As an emerging growth company, it follows reduced reporting requirements and warns investors about high investment risk, potential dilution from this and future equity issuances, and the possibility of Nasdaq delisting if listing standards are not maintained.
OKYO Pharma Limited has transitioned its at-the-market equity offering facility to Leerink Partners LLC, replacing its prior arrangement with B. Riley Securities. Leerink will act as exclusive sales agent, able to sell OKYO common shares into the market from time to time at prevailing prices.
The ATM program is intended to give OKYO ongoing access to equity capital, at the Company’s discretion and subject to market conditions, with Leerink earning a commission equal to 3.0% of gross proceeds from any shares sold. Management highlights this as enhancing financial flexibility to fund clinical development, including the lead candidate urcosimod for neuropathic corneal pain.
OKYO Pharma Ltd. has established an at the market offering program allowing it to sell up to $50,000,000 of ordinary shares through Leerink Partners LLC as sales agent or principal.
The shares will be issued under OKYO’s effective Form F-3 shelf registration and a related prospectus supplement. Leerink Partners will receive a 3.0% cash commission on gross sales and reimbursement of specified expenses. OKYO is not required to sell any minimum amount and either party can suspend the program, so the total capital ultimately raised and commissions paid are not yet determinable.
OKYO Pharma Limited is establishing an at-the-market program to sell up to $50 million of ordinary shares through Leerink Partners on Nasdaq under the symbol OKYO.
Leerink Partners will act as sales agent or principal and earn a 3% commission on gross proceeds. Based on an illustrative price of $1.99, the company shows a scenario where shares outstanding could rise from 40,555,197 to up to 65,680,825, highlighting potential dilution for new and existing holders.
OKYO plans to use any net proceeds for clinical development, general corporate purposes and working capital, with a primary focus on advancing its lead drug candidate urcosimod for neuropathic corneal pain, an indication with no FDA‑approved therapies. Urcosimod has Fast Track designation and encouraging Phase 2a and dry eye disease data, but the company notes significant risks, including ongoing losses, future financing needs, and the possibility of Nasdaq delisting.